A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expressed, MYCN-driven oncoprotein on small-cell lung cancers (SC...

Descripción completa

Detalles Bibliográficos
Autores principales: Raman, Swetha, Buongervino, Samantha N., Lane, Maria V., Zhelev, Doncho V., Zhu, Zhongyu, Cui, Hong, Martinez, Benjamin, Martinez, Daniel, Wang, Yanping, Upton, Kristen, Patel, Khushbu, Rathi, Komal S., Navia, Carmen T., Harmon, Daniel B., Li, Yimei, Pawel, Bruce, Dimitrov, Dimiter S., Maris, John M., Julien, Jean-Philippe, Bosse, Kristopher R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324494/
https://www.ncbi.nlm.nih.gov/pubmed/34337560
http://dx.doi.org/10.1016/j.xcrm.2021.100344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324494/
https://www.ncbi.nlm.nih.gov/pubmed/34337560
http://dx.doi.org/10.1016/j.xcrm.2021.100344

Ejemplares similares